Literature DB >> 6470141

Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine.

M D McGoon, P M Vanhoutte.   

Abstract

To examine the effect of platelets and 5-hydroxytryptamine on pulmonary arterial smooth muscle, rings of canine pulmonary arteries, with and without endothelium, were studied under isometric conditions in physiological salt solution. 5-Hydroxytryptamine, but not the thromboxane-like endoperoxide analogue U-46619, produced concentration-dependent contractions of the rings with a maximum averaging 93% of that obtained with KC1. Autologous platelets in concentrations comparable to that in plasma caused contractions averaging 70% of the maximal responses to KC1. Solution withdrawn from baths containing platelet-contracted rings, but not the supernatant from nonaggregated platelets, also caused contraction. The serotonergic antagonists cyproheptadine, ketanserin, and methysergide caused concentration-dependent inhibition and eventually abolition of contractions evoked by platelets and 5-hydroxytryptamine. Phentolamine and prazosin produced significantly less inhibition of the contractile response to platelets. Pretreatment of the platelets with indomethacin or meclofenamate reduced thromboxane release but had no effect on platelet-induced contractions. Removal of the endothelium did not affect contractile responses to platelets or 5-hydroxy-tryptamine. These experiments demonstrate that in the canine pulmonary artery: (a) 5-hydroxytryptamine is the predominant mediator of the contractile response triggered by platelet aggregation; and (b) unlike in other blood vessels, the endothelium cannot curtail the contractile response to aggregating platelets.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6470141      PMCID: PMC425237          DOI: 10.1172/JCI111499

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Reduction of platelet serotonin and the response to pulmonary emboli.

Authors:  C B Rosoff; E W Salzman; V Gurewich
Journal:  Surgery       Date:  1971-07       Impact factor: 3.982

2.  Prostaglandin release and the interaction of platelets with the pulmonary vasculature of rat and guinea pig.

Authors:  J A Boyd; T E Eling
Journal:  Thromb Res       Date:  1980 Jul 1-15       Impact factor: 3.944

3.  The site of pulmonary vasomotor activity during hypoxia or serotonin administration.

Authors:  M A Sackner; D H Will; A B DuBois
Journal:  J Clin Invest       Date:  1966-01       Impact factor: 14.808

4.  Contractile responses of canine isolated pulmonary lobar arteries and veins to norepinephrine, serotonin, and tyramine.

Authors:  P D Joiner; P J Kadowitz; L B Davis; A L Hyman
Journal:  Can J Physiol Pharmacol       Date:  1975-10       Impact factor: 2.273

5.  Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.

Authors:  J M Van Nueten; P A Janssen; J Van Beek; R Xhonneux; T J Verbeuren; P M Vanhoutte
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

6.  Differential effects of prostaglandins on canine intrapulmonary arteries and veins.

Authors:  B M Altura; N Chand
Journal:  Br J Pharmacol       Date:  1981-08       Impact factor: 8.739

7.  Platelet-mediated pulmonary hypertension and hypoxia during pulmonary microembolism: reduction by platelet inhibition.

Authors:  J Mlczoch; A Tucker; E K Weir; J T Reeves; R F Grover
Journal:  Chest       Date:  1978-12       Impact factor: 9.410

8.  Indium-111 tropolone, a new high-affinity platelet label: preparation and evaluation of labeling parameters.

Authors:  M K Dewanjee; S A Rao; P Didisheim
Journal:  J Nucl Med       Date:  1981-11       Impact factor: 10.057

9.  Pulmonary inactivation of serotonin and site of serotonin pulmonary vasoconstriction.

Authors:  D A Rickaby; C A Dawson; M B Maron
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1980-04

10.  Effect of imidazole on renal function in unilateral ureteral-obstructed rat kidneys.

Authors:  J C Strand; B S Edwards; M E Anderson; J C Romero; F G Knox
Journal:  Am J Physiol       Date:  1981-06
View more
  11 in total

Review 1.  Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension.

Authors:  P Egermayer; G I Town; A J Peacock
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction.

Authors:  Robert F Wideman; Krishna R Hamal
Journal:  J Pharmacol Toxicol Methods       Date:  2011-01-26       Impact factor: 1.950

3.  Role of basal extracellular Ca2+ entry during 5-HT-induced vasoconstriction of canine pulmonary arteries.

Authors:  Sean M Wilson; Helen S Mason; Lih C Ng; Stephen Montague; Louise Johnston; Neil Nicholson; Sarah Mansfield; Joseph R Hume
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

4.  Pulmonary hypertension and dexfenfluramine.

Authors:  P Cacoub; R Dorent; P Nataf; J P Houppe; J C Piette; P Godeau; I Gandjbakhch
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 5.  Current management of patients with pulmonary hypertension and right ventricular insufficiency.

Authors:  S R Hankins; E M Horn
Journal:  Curr Cardiol Rep       Date:  2000-05       Impact factor: 2.931

Review 6.  Platelets in lung biology.

Authors:  Andrew S Weyrich; Guy A Zimmerman
Journal:  Annu Rev Physiol       Date:  2012-10-01       Impact factor: 19.318

7.  Effects of tryptamine mediated through 2 states of the 5-HT2 receptor in calf coronary artery.

Authors:  M Frenken; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-05       Impact factor: 3.000

Review 8.  Serotonin and the vascular system. Role in health and disease, and implications for therapy.

Authors:  D S Houston; P M Vanhoutte
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

Review 9.  Gas exchange and pulmonary hypertension following acute pulmonary thromboembolism: has the emperor got some new clothes yet?

Authors:  John Y C Tsang; James C Hogg
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

10.  Primary pulmonary hypertension and fenfluramine use.

Authors:  F Brenot; P Herve; P Petitpretz; F Parent; P Duroux; G Simonneau
Journal:  Br Heart J       Date:  1993-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.